(RTTNews) - BioNTech SE (BNTX) and Bristol Myers Squibb Company (BMY) announced first data from the Phase 2 ROSETTA Lung-107 clinical trial evaluating pumitamig plus docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after firs